Business
Medicenna Solidifies Superkine Platform with Additional US Patent Issuance
Medicenna Solidifies Superkine Platform with Additional US Patent Issuance Canada ...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna Solidifies Superkine Platform with Additional US Patent Issuance\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, TX, Oct. 24, 2017\n\n\n\nTORONTO and HOUSTON, TX, Oct. 24, 2017 /CNW/ - Medicenna Therapeutics Corp. (\"Medicenna\" or the \"Company\") (TSX: MDNA; OTCQX: MDNAF), a clinical stage immuno-oncology company, developing first-in-class proprietary cytokines, today announced that the United States Patent and Trademark Office issued another patent related to the Company's Superkine platform. U.S. Patent 9,738,696 (\"Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities\") issued to the Board of Trustees of the Leland Stanford Junior University and licensed exclusively to Medicenna, covers the composition of engineered interleukin-4 (\"IL-4\") Superkines. \n\n\"The issuance of the IL-4 patent, along with issued patents covering our IL-2 and IL-13 Superkines, solidifies our leadership position in developing a series of unique and versatile interleukins that represent key pillars of our next generation platform of immunotherapies,\" said Dr. Fahar Merchant, Chairman, President and CEO of Medicenna Therapeutics. \"We remain focused on maximizing the value of our leading-edge Superkine platform through advancing these novel super-agonists and super-antagonists into clinical development on our own and with potential partners.\" \n\nMedicenna continues to protect its Superkine and Empowered Cytokine platforms which comprises of over 40 filed or issued patents in key territories including the US, Canada, EU and Asia.\n\nSuperkines have exceptionally high selectivity and affinity for receptor sub-types, resulting in superior safety and efficacy. Proof of concept results published in leading scientific journals have demonstrated the significant potential of these Superkine agonists and antagonists to address unmet needs in oncology, inflammatory and other immune mediated diseases.\n\nAbout Medicenna Therapeutics Corp. Medicenna is a clinical stage immuno-oncology company develo...